

# Antimicrobial therapy

**Antimicrobial Therapy** refers to the use of agents, such as **antibiotics**, **antifungals**, **antivirals**, and antiparasitics, to treat infections caused by **microorganisms**, including **bacteria**, **fungi**, **viruses**, and parasites. The primary goals of antimicrobial therapy are to eradicate the causative pathogen, minimize harm to the host, and prevent the development of antimicrobial resistance. Here's a general overview:

—

### **1. Types of Antimicrobials - Antibiotics:** Target bacteria (e.g., penicillin, ciprofloxacin). - **Antifungals:** Target fungi (e.g., fluconazole, amphotericin B). - **Antivirals:** Target viruses (e.g., oseltamivir, remdesivir). - **Antiparasitics:** Target parasites (e.g., metronidazole, ivermectin).

—

### **2. Principles of Antimicrobial Therapy - Empirical Therapy:** Initiated before the exact pathogen is identified, often based on clinical judgment and epidemiological data. - **Targeted Therapy:** Based on the identification of the pathogen and its susceptibility profile. - **Prophylactic Therapy:** Used to prevent infections, particularly in high-risk populations or surgical settings. - **Combination Therapy:** Employing multiple agents to broaden the spectrum, achieve synergistic effects, or prevent resistance.

—

### **3. Pharmacokinetics and Pharmacodynamics - Absorption, Distribution, Metabolism, and Excretion:** These factors determine how the antimicrobial reaches and maintains therapeutic levels at the site of infection. - **Concentration-Dependent Killing:** Efficacy increases with drug concentration (e.g., aminoglycosides). - **Time-Dependent Killing:** Efficacy relies on maintaining levels above the minimum inhibitory concentration (MIC) for an extended period (e.g., beta-lactams).

—

### **4. Resistance and Stewardship - Antimicrobial Resistance (AMR):** A critical challenge where pathogens no longer respond to treatments due to misuse or overuse of antimicrobials. - **Antimicrobial Stewardship Programs (ASP):**

1. Ensure the appropriate selection, dosage, and duration of therapy.
  2. Monitor resistance trends.
  3. Educate healthcare providers on responsible use.
- 

### **5. Key Considerations in Antimicrobial Therapy - Host Factors:** Age, immune status, renal/hepatic function, allergies. - **Pathogen Factors:** Susceptibility patterns, virulence. - **Drug Factors:** Side effects, drug interactions, cost, and formulation.

—

### **6. Examples of Guidelines - Community-Acquired Pneumonia (CAP):** Empiric therapy often includes beta-lactams combined with macrolides or respiratory fluoroquinolones. - **Sepsis:**

Broad-spectrum antibiotics initiated promptly, later narrowed based on cultures. - **Tuberculosis:** Long-course therapy with multiple agents like isoniazid and rifampin to prevent resistance.

**Postoperative intracranial neurosurgical infections** (PINI) complicate < 5% neurosurgeries. Scarce attention was dedicated to the extension and characteristics of its antimicrobial management considering their high morbidity, not negligible mortality, delayed hospital stay and increased healthcare costs.

They analyzed **retrospectively** (2014-2023) 162 PINI from eight Spanish third-level **academic hospitals**.

**Elective** clean craniotomies after tumor or vascular causes were the leading procedures. **Epidural abscess** (24.7%), **scalp infections** (19.8%), **postsurgical meningitis** (16.7%) and **cranioplasty infections** (16.7%) were the most frequent PINI. **Gram negative bacteria** (38.6%) and Staphylococcus spp (28.6%) were the predominant isolates. Overall 85.2% patients underwent **pus** drainage, mostly by **craniotomy** (40.3%). Interestingly 34% were already receiving **antibiotics** for extracranial infections before developing PINI while 16.8% did not receive pre-operative antibiotic prophylaxis. In total 77.2% patients started a combined intravenous (IV) antimicrobial therapy, of which 85.2% switched after 5 days to a second-line IV antibiotic regimen, in 41.3% cases combined, after pus culture results, for a median of 21 days. Overall 61.1% patients continued on oral antimicrobials after hospital discharge, 30.3% as a combined regimen, for a median of 42 days. Complete cure was obtained in 81.5% cases, while 11.1% relapsed, 7.4% failed to cure and 6.8% died after PINI complications. In the **multivariate** analysis oral antimicrobial therapy after hospital discharge ( $p = 0.001$ ) was significantly associated with PINI cure with no effect on survival.

They conclude that an extended 6 weeks sequential IV and oral antimicrobial therapy in addition to neurosurgical correction increases PINI cure rate with no effect on survival <sup>1)</sup>

1)

Asensi V, Vázquez-Fernández C, Suárez-Díaz S, Asensi-Díaz E, Carrasco-Antón N, García-Reyne A, Panero I, Muñoz MV, Guerra JM, Arístegui J, Sepúlveda MA, García-Calvo X, Dueñas C, Biosca M, Chiminazzo V, Collazos J. Extended sequential intravenous and oral antimicrobial therapy improves cure rate in postoperative intracranial neurosurgical infections: a Spanish multicenter retrospective study. BMC Infect Dis. 2024 Nov 26;24(1):1345. doi: 10.1186/s12879-024-10204-7. PMID: 39587499.

From:

<https://neurosurgerywiki.com/wiki/> - **Neurosurgery Wiki**

Permanent link:

[https://neurosurgerywiki.com/wiki/doku.php?id=antimicrobial\\_therapy](https://neurosurgerywiki.com/wiki/doku.php?id=antimicrobial_therapy)

Last update: **2024/11/27 07:35**

